COMP <GO>
EOLS vs AQST // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Evolus Inc. (NASDAQ) VS. Aquestive Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 7
— AQST 1
■ METRIC PARITY
LAST: $7.16 (-2.58%) • MKT CAP: $485.5M
options-implied-move
—
LAST: $3.77 (-3.08%) • MKT CAP: $488.2M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. AQST)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EOLS | AQST | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 66.30% | 58.30% | +8.00 | EOLS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.20% | -10.45% | +1.25 | EOLS | /fcf-yield <GO> |
| Operating Margin | -11.00% | -60.00% | +49.00 | EOLS | /operating-margins <GO> |
| Net Profit Margin | -17.40% | -60.00% | +42.60 | EOLS | /net-margins <GO> |
| Revenue Growth (YoY) | 11.60% | -22.60% | +34.20 | EOLS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 0.20 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 3/9 | +1.00 | EOLS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.4 | 39.2 | +7.20 | EOLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $485.5M | $488.2M | -$2.8M | AQST | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EOLS REV | AQST REV | EOLS GROSS % | AQST GROSS % | EOLS FCF | AQST FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $297.2M | $44.5M | 66.3% | 58.3% | -$45.7M | -$53.0M |
| FY 2024 | $266.3M | $57.6M | 68.5% | 69.0% | -$19.5M | -$35.9M |
| FY 2023 | $202.1M | $50.6M | — | — | -$34.0M | -$6.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
AQST // BETA —